¥í¥°¥¤¥ó¤·¤Æ¤µ¤é¤Ëmixi¤ò³Ú¤·¤â¤¦

¥³¥á¥ó¥È¤òÅê¹Æ¤·¤Æ¾ðÊó¸ò´¹¡ª
¹¹¿·ÄÌÃΤò¼õ¤±¼è¤Ã¤Æ¡¢ºÇ¿·¾ðÊó¤ò¥²¥Ã¥È¡ª

mixiÁí¹ç°åÎÅ¥»¥ó¥¿¡¼¥³¥ß¥å¤Î»Ò¶¡¤ÎÉ÷¼ÙÌô¤Ø¤ÎÉÍϻϺ»á¤Î¥³¥á¥ó¥È

  • mixi¥Á¥§¥Ã¥¯
  • ¤³¤Î¥¨¥ó¥È¥ê¡¼¤ò¤Ï¤Æ¤Ê¥Ö¥Ã¥¯¥Þ¡¼¥¯¤ËÄɲÃ
º£Æü¤ÎÆÉÇ俷ʹ¡¢°åÎÅ¥ë¥Í¥µ¥ó¥¹¤Îµ­»ö¤«¤é¤Ç¤¹¡£

º£Ç¯£±·îÊƹñ¤Ë¤ÆÌô±Õ¤ò¥¹¥Ý¥¤¥È¤Ç·×Î̤¹¤ë
ÆüËܤˤϤʤ¤·ÁÂÖ¤ÎÉ÷¼ÙÌô¤Ç¡¢
²á¾êÅêÍ¿¤Ë¤è¤ê³±»ß¤áÌô¤ò°û¤ó¤À
£±ºÐ̤Ëþ»ù¤Î»àË´Îã
£³·ï¤ÎÊó¹ð¤¬¤¢¤Ã¤¿¤È¤Î»ö¡£
¤½¤Î¸å¾®»ù²Ê°å¤é¤ÎƯ¤­¤«¤±¤Ë¤è¤ê
£±£°·îÊÆ¿©ÉÊ°åÌôÉʶɡʣƣģÁ¡Ë¤Î
¾®»ù°åÎŤ˴ؤ¹¤ë»ðÌä°Ñ°÷²ñ¤Ï¡¢
¥É¥é¥Ã¥°¥¹¥È¥¢¤Ê¤É¤Ç
°å»Õ¤Î½èÊý¤Ê¤·¤ÇÇ㤨¤ëÉ÷¼ÙÌô¤ä³±»ß¤áÌô¤ò¡¢
6ºÐ̤Ëþ¤Î»Ò¶¡¤Ë»ÈÍѤ¹¤ë¤Ù¤­¤Ç¤Ï¤Ê¤¤¤ÈFDA¤Ë´«¹ð¤·¤¿¡£

¤³¤ì¤ËÂФ·ÆüËÜÂç½°Ìô¹©¶È¶¨²ñ¤Ï
¡ÖÆüËܤΥ·¥í¥Ã¥×ºÞ¤ÏÇ»ÅÙ¤¬
¡¡ÊƹñÀ½ÉʤΣ±£°¡Á£²£°Ê¬¤Î£±¤Ç½ÅÂç¤Ê»ö¸Î¤Ï
¡¡µ¯¤­¤Æ¤¤¤Ê¤¤¤¬¡¢ÍÑË¡¡¢ÍÆÎ̤θ·¼é¤ò¡×
¤È¸Æ¤Ó¤«¤±¤¿¡£

¹ñÆâ¤Ç¤â»ÔÈΤÎÉ÷¼ÙÌô¤Ë¤è¤ëÇٱꡢ´Î±ê¡¢¸ÆµÛº¤Æñ¤Ê¤É¤Î
½Å¤¤ÉûºîÍѤϺòǯ£±£²£¹·ïÊó¹ð¤µ¤ì¤Æ¤¤¤ë¡£

°åÌô¥Ó¥¸¥é¥ó¥¹¥»¥ó¥¿¡¼¤ÎÉÍϻϺ°å»Õ¤Î¥³¥á¥ó¥È
¡ÖÆüËܤÎÉ÷¼ÙÌô¤Ë¤âÊƹñ¤ÈƱÍͤÎÀ®Ê¬¤¬»È¤ï¤ì¤Æ¤ª¤ê
¡¡¾®»ù¤Ø¤Î¸ú²Ì¤Î΢¤Å¤±¤¬Ìµ¤¯¡¢
¡¡ÉûºîÍѤζ²¤ì¤¬¤¢¤ë¤Î¤ÏƱ¤¸¤À¡£¡×
¡Ö°å»Õ¤¬½èÊý¤¹¤ëÉ÷¼ÙÌô¤ÏÀ®Ê¬¤¬»ÔÈÎÌô¤Î
¡¡£±,£µ¡Á£²ÇÜ¿¤¯´Þ¤Þ¤ì¡¢ÉûºîÍÑ¤Î´í¸±¤Ï¤è¤êÂ礭¤¤¡£
¡¡»ÔÈÎÌô¡¢½èÊýÌô¤È¤â£¶ºÐ̤Ëþ¤Ï¶Ø»ß¤Ë¤¹¤Ù¤­¤À¡£¡×
¤È¤Î»ö¡£

Êƹñ¤Ç¤Ï´«¹ð¤ò¼õ¤±£Æ£Ä£Á¤Ï¾®»ù¤Ø¤Î
»ÈÍѵ¬À©¤ò¹Ô¤¦¤«¸¡Æ¤¤·¤Æ¤ª¤ê¡¢
¸üÀ¸Ï«Æ¯¾Ê¤ÏÊÆÅö¶É¤ÎÂбþ¤ò¸«¼é¤ê¤¿¤¤¤È¤Î»ÑÀª¡£

¡¦¡¦¡¦»ÔÈÎÌô¤Îµ¬À©¤ò¤¤¤­¤Ê¤ê
°å»Õ¤Î½èÊýÌô¤Ë¤Þ¤ÇÈôÌö¤µ¤»¤ëÏÀÅÀ¤Ë
À褺°¢Á³¤È¤·¤¿¤Î¤Ç¤¹¤¬¡¢
¥³¥á¥ó¥È¤·¤¿¤Î¤¬¤¢¤ÎÉÍϻϺ»á¤È¸À¤¦»ö¤Ç
ËͤÎÌܤ˼㴳¤Î¥Ð¥¤¥¢¥¹¤¬¤«¤«¤Ã¤Æ¤¤¤ë»ö¤â¤¢¤ê¡¢
³§¤µ¤ó¤Ë¤´°Õ¸«¤ò»Ç¤¤¤¿¤¯»×¤¤¤Þ¤¹¡£
ÉÍϻϺ»á¤Î°Õ¸«¤Ëº£²ó¤Ï°ìÍý¤¢¤ë¤È¸«¤ë¤Ù¤­¤Ç¤·¤ç¤¦¤«¡©


¥³¥á¥ó¥È(35)

¡ä£±,£µ¡Á£²ÇÜ¿¤¯´Þ¤Þ¤ì¡¢ÉûºîÍÑ¤Î´í¸±¤Ï¤è¤êÂ礭¤¤¡£
¤³¤ÎÄøÅÙ¤ÇÌäÂ꤬À¸¤¸¤ë¤Î¤Ï¥ê¥É¥«¥¤¥ó¤ä¥¸¥´¥­¥·¥ó¤Ê¤É¤Î¡¢±Ô¤¹¤®¤ëÌôʪ¤¯¤é¤¤¤«¤È¡Ä
¤È¤¤¤¦¤«¡¢¤³¤ÎÄøÅ٤κ¹¤Ï¾Ã²½¹ÚÁǤγèÀ­¤äºÞ·Á¤Ç¤¤¤¯¤é¤Ç¤â¤Ò¤Ã¤¯¤êÊÖ¤ë¤ó¤¸¤ã¡©

Ìôʪ¡¢¤³¤È»ÔÈΤµ¤ì¤Æ¤¤¤ëʪ¤Ë¤Ä¤¤¤Æ¤Ï¿¾¯¤ÎÁý¸º¤¬¤¢¤Ã¤¿¤È¤·¤Æ¤âÃæÆǤÏ(±Ö³ØŪ¤ËÍ­°Õ¤Ë¤Ï)µ¯¤­¤Ê¤¤¤â¤Î¤¬ºÎÍѤµ¤ì¤Þ¤¹¡£¶Ëü¤ÊÎã¤À¤È·å°ì¤Ä°ã¤Ã¤Æ¤âÊ¿µ¤¤Ê¤â¤Î¤â¤¢¤ê¤Þ¤¹¡£
¤³¤ÎÊդϥ¢¥á¥ê¥«¤ÈÆüËܤÎÌôʪ´ÞÍ­Î̤ΰ㤤¤ò¸«¤Æ¤âʬ¤«¤ê¤Þ¤¹¤Í¡£

¤¿¤À¡¢¾®»ù¤ËÂФ¹¤ëÅêÍ¿¤Ï¿µ½Å¤µ¤ò˺¤ì¤ë¤Ê¤Ã¤Æ°ÕÌ£¤Ç²ò¼á¤¹¤ë¤Ê¤é¤¤¤¤¤ó¤¸¤ã¤Ê¤¤¤«¤È¡£
Æä˺£¤Ï¾®»ù°åÎŤμõ¤±»®¤¬¤¢¤Þ¤êÀ°¤Ã¤Æ¤¤¤ë¤È¤Ï¸À¤¨¤Ê¤¤(¤È¤¤¤¦À¤´Ö¤ÎɾȽ¤â°ìÉô¤¢¤ë)¤Î¤Ç¡£
¤Ø¤ó¤Ê¤ª¤¸¤µ¤ó¡ä
¤ß¡¼¤ä¤ó¤µ¤ó¡ä
¥³¥á¥ó¥ÈÍ­Æñ¤¦¤´¤¶¤¤¤Þ¤¹¡£
¥¿¥ß¥Õ¥ë¤ÎÈ÷ÃßÃæ»ß´«¹ð¤Ê¤É
²á·ã¤Êȯ¸À¤¬Â¿¤¤ÉÍ»á¤Îȯ¸À¤æ¤¨¤Ë¡¢
»Ï¤á¤ÏËͤ⵭»ö¤ò¿¿ÌÌÌܤË
Æɤ൤̵¤¯¤·¤Þ¤·¤¿¡£

¤Ì¤Ó¤µ¤ó¡ä
¥³¥á¥ó¥È¤¢¤ê¤¬¤È¤¦¤´¤¶¤¤¤Þ¤¹¡£
¼Â¤Ïº£²ó°ìÈÖ¥³¥á¥ó¥È夭¤¿¤«¤Ã¤¿Êý¤Ç¤·¤¿¡£
¾®»ù¤Ø¤ÎÉ÷¼ÙÌô½èÊý¤Ë¤Ä¤¤¤Æ¤Ï

2ºÐ̤Ëþ¤Ø¤Î³±»ß¤á¤ÈÉ÷¼ÙÌôÅêÍ¿¤ËÃí°Õ
Æü·Ð¥á¥Ç¥£¥«¥ë¤è¤ê
http://medical.nikkeibp.co.jp/leaf/mem/pub/hotnews/int/200701/502289.html
Åù¤Ç¤â¼è¤ê¾å¤²¤é¤ì¤Æ¤¤¤Þ¤¹¤¬¡¢
̤¤À¥¨¥Ó¥Ç¥ó¥¹¤¬½½Ê¬¤È¤Ï¸À¤¤Æñ¤¯¡¢
»Ò¶¡¤ÎÉ÷¼Ù¤Î¾É¾õ¤òϤ餲¤ë¤è¤ê¤â
¿Æ¤ÎÉ԰¤òϤ餲¤ë°Ù¤Ë
É÷¼Ù¤ÎÌô¤ò½èÊý¤µ¤ì¤ë¥±¡¼¥¹¤â¤¢¤ë¤è¤¦¤Ë»×¤ï¤ì¤Þ¤¹¡£
¡ä£µ¤ÎÌë³°¤µ¤ó¤Î»ØŦ¤µ¤ì¤ë¤È¤ª¤ê¡¢
¾®»ù¤Ø¤ÎÉ÷¼ÙÌô¤ÎÆâÉþÅêÍ¿¤Ø¤Î¿µ½Å¤µ¤òµá¤á¤ëÄó¸À¤È²ò¼á¤¹¤ì¤Ð¡¢
°ìÍý¤¢¤ë¤«¤Ê¡¢¤È¤â»×¤¨¤¿¤Î¤Ç
¤¢¤¨¤Æ¥È¥Ô¥Ã¥¯Î©¤Æ¤·¤Æ¤ß¤Þ¤·¤¿¡£

ÈÖŤµ¤ó¡ä
¥³¥á¥ó¥È失¤Æ¸÷±É¤Ç¤¹¡£

¡ÖChanges in Antihypertensive Prescribing During US Outpatient Visits for Uncomplicated Hypertension Between 1993 and 2004¡×
¤Ë¤¢¤ë¤è¤¦¤Ë¡¢ÍøÇ¢Ìô¤Ç¤Î¹ß°µ¤ÇÎɤ¤¤È¤¹¤ë°ÕÌ£¤È²ò¼á¤·¤ÆÎɤ¤¤Ç¤·¤ç¤¦¤«¡©




¤³¤ÎÉÍϻϺ¤µ¤ó¤¬¤É¤Î¤¯¤é¤¤¶¸¤Ã¤Æ¤¤¤ëÅÛ¤À¤«¤Ï¤·¤ê¤Þ¤»¤ó¤¬¤À¤«¤é¤È¤¤¤Ã¤Æ»ÔÈÎÌô¤ÏÉûºîÍѤ沤ì¤Ï¿´Çۤʤ¤¤È¤¤¤¦¤Î¤Ï¤ª¤«¤·¤¤¤È»×¤¤¤Þ¤¹¡£ÉûºîÍѤο´ÇÛ¤·¤Ê¤¯¤Æ¤¤¤¤Ìô¤Ê¤ó¤Æ¤¢¤ë¤ó¤Ç¤·¤ç¤¦¤«¡©¡¡»ÀÁǤÀ¤Ã¤Æ¥ä¥Ð¤¤¤¸¤ã¤Ê¤¤¤Ç¤¹¤«¡£¤Þ¤¢³±¤ÎÌô¤½¤Î¤â¤Î¤¬¤¢¤ó¤Þ¤ê¸ú¤¯¤â¤Î¤Ç¤Ï¤Ê¤¤¤·¤Þ¤¿¤È¤¯¤Ë¥¢¥á¥ê¥«¤Ç¤Ï¥Ð¥«¤Ê¿Æ¤¬Â¿¤¤¤Î¤Ç³±¤¬¤È¤Þ¤é¤ó¤È¥°¥Ó¥°¥Ó°û¤Þ¤»¤é¤ì¤ë»Ò¶¡Ã£¤¬´í¤Ê¤¤¤ï¤±¤Ç¤¹¡£¤â¤·evidence-based medicine¤Îµ´¤ÎÍͤËÂбþ¤¹¤ë¤Î¤¬°å»Õ¤Î»Å»ö¤À¤È¤·¤¿¤é³±»ß¤á¤ò£²ºÐ°Ê²¼¤É¤³¤í¤«£¶ºÐ°Ê²¼¤Î»Ò¶¡¤Ë¤¢¤²¤ë¤Î¤ÏŪ³°¤ì¤Ç¤Ï¤Ê¤¤¤Ç¤·¤ç¤¦¤«¡©¡¡ÃΤäƤë¸Â¤ê¤Ç¤Ï¤³¤Îage group ¤Ë¤¿¤¤¤·¤Æ¤Îefficacy¤ò΢ÉÕ¤±¤ëʸ¸¥¤Ï¤Ê¤¤¤È¤ª¤â¤¤¤Þ¤¹¡£¤À¤¤¤¿¤¤³±¤òϤ餲¤ë»ö¤¬Áá´ü²óÉü¤Ë¤Ä¤Ê¤¬¤ë¤Î¤«¤È¤¤¤¦ÁÇËѤʼÁÌä¤âÉ⤫¤ó¤Ç¤­¤Þ¤¹¡£

¡ä¡ä¼Â¤Ïº£²ó°ìÈÖ¥³¥á¥ó¥È夭¤¿¤«¤Ã¤¿Êý¤Ç¤·¤¿¡£

¥¢¥á¥ê¥«¤Î¥é¡¼¥á¥ó²°¤Î¿ÆÉã¤Ë²¿¤¬¤ï¤«¤ë¤ó¤À¡¢ÃΤ俤«¤Ö¤ê¤¹¤ë¤ó¤¸¤ã¤Í¤¨¤è¤È¤«¤¤¤¦¥á¡¼¥ë¤¬»¦Åþ¤·¤Æ¤¤¤Þ¤¹¤¬¤½¤ÎÊդ覽¤°å¤è¤ê¤Ï¤è¤¯¤·¤Ã¤Æ¤Þ¤¹¤¼¡£¥Õ¥¡¥ó¥á¡¼¥ë¤âƱ¤¸°Ì夤¤Æ¤¤¤ë¤Î¤Ç¤¢¤Þ¤ê½ý¤Ä¤­¤Þ¤»¤ó¤Ç¤·¤¿¤¬¡£
¤Ì¤Ó¤µ¤ó¡ä
¤È¤Æ¤â¾®»ùµßµÞ¤Ë¾Ü¤·¤¤¥é¡¼¥á¥ó²°Å¹Ä¹¤µ¤ó¡¢
Ì©¤«¤ËËͤâ¥Õ¥¡¥ó¤À¤Ã¤¿¤ê¤·¤Þ¤¹¡£
»Ò¶¡¤ÎÉ÷¼Ù¤Ë½èÊý¤µ¤ì¤ë¹³¥Ò¥¹¥¿¥ß¥óÌô¡¢
³±»ß¤áÌô¤Ë¤Ä¤¤¤Æ¤ÏË⵿ͤÌä¤ò´¶¤¸¤Æ¤¤¤Þ¤¹¡£
ɸ¶ÂΤòÇÓ½ü¤¹¤ëƯ¤­¤òµÕ¤Ë²¡¤µ¤¨¹þ¤ó¤Ç¤·¤Þ¤¦
Ìõ¤Ç¤¹¤«¤é¤Í¡¦¡¦¡¦

¤Ø¤ó¤Ê¤ª¤¸¤µ¤ó¡ä
³Î¤«¤Ëº£²ó¤Î£Æ£Ä£Á¤Î´«¹ð¤Ï
³±»ß¤áÌô¡¢¤¯¤·¤ã¤ß¡¢É¡¿å¤ò²¡¤µ¤¨¤ë
¹³¥Ò¥¹¥¿¥ß¥óºÞ¤ò´Þ¤àÉ÷¼ÙÌô¤Ë¸ÂÄꤷ¤Æ¤¤¤Þ¤¹¡£

Ëͤ⥢¥»¥È¥¢¥ß¥Î¥Õ¥§¥óÅù¤Î²òÇ®ÄÃÄËÌô¤Ï
ÅêÍ¿»þ´ü¤ò¸í¤é¤Ê¤±¤ì¤ÐÍ­¸ú¤ÊÌôºÞ¤Ç¤¹¤·¡¢
ºÙ¶Ý´¶À÷¤Ë¤è¤ëÇÙ±ê¤Ë¹³À¸ºÞ¤Î½èÊý¤Ï
ɬÍפǤ¢¤ë¤È¹Í¤¨¤Æ¤¤¤Þ¤¹¡£
ÉÍ»á¤ÎÄó¸À¤òÁ´¤ÆÎɤ·¤È¤·¤¿Ìõ¤Ç¤Ï¤¢¤ê¤Þ¤»¤ó¡£

¥¢¥á¥ê¥«¤Ï¹³À¸ºÞ¤â¥É¥é¥Ã¥°¥¹¥È¥¢¤ÇÇ㤨¤Þ¤¹¤«¤é¤Í¡£
ήÀм«¸ÊÀÕǤ¤Î¹ñ¤Ã¤Æ¤È¤³¤í¤Ç¤·¤ç¤¦¤«¡£


¡ä¡ä¥¢¥á¥ê¥«¤Ï¹³À¸ºÞ¤â¥É¥é¥Ã¥°¥¹¥È¥¢¤ÇÇ㤨¤Þ¤¹¤«¤é¤Í¡£

½èÊý䵤ͤ¨¤ÈÇ㤨¤Í¤¨¤¼¡£¥á¥­¥·¥³¹Ô¤±¤Ð¤Ê¤ó¤Ç¤âÇ㤨¤Þ¤¹¤¬¡£
ßÀϻϺ¤µ¤ó¤Ï¡¢³Î¿®ÈȤȤ·¤Æ¡¢Á±°Õ¤Ç¡¢ÍÍ¡¹¤Ê°åÌô¤ÎÉûºîÍѤˤè¤ë³²¤ò¤Ê¤¯¤½¤¦¤ÈÅؤá¤Æ¤¤¤ë¿Í¤Î¤è¤¦¤Ç¤¹¡£
°ìÈ̿ͤÈÀìÌç²È¡¢Áê¼ê¤Ë¤è¤Ã¤Æ¸ì¤êÊý¤òÊѤ¨¤Æ¤¤¤Þ¤¹¤·¡¢°ìÍý¤¢¤ëÉôʬ¤â³Î¤«¤Ë¤¢¤ë¡£
°ìÈ̸þ¤±¤Ë¤Ï¤«¤Ê¤ê¶ËÏÀ¤ò¸ì¤ë¤±¤É¡¢ÀìÌç²È¤ËÂФ·¤Æ¤ÏÂÅÅö¤ÇÈ¿ÏÀ¤·¤Ë¤¯¤¤ÆâÍƤòÏÀÍýŪ¤Ë½Ò¤Ù¤é¤ì¤ë¡£
¼ÂºÝËܿͤò¸«¤ë¤È¡¢£·£°²á¤®¤È¤Ï»×¤¨¤Ê¤¤¤Û¤É¼ã¡¹¤·¤¯¡¢·ø¶ì¤·¤¤³Ø¼Ô¤ËÈæ¤Ù¤Æ¡¢¿Í´ÖŪ̥ÎϤ⤢¤ë¤Î¤è¤Í¤ó¡£
Äì¤ÎÀõ¤¤¥È¥ó¥Ç¥â¤µ¤ó¤Ë²á¤®¤Ê¤¤¤È¤¤¤¦Ç§¼±¤Ç¸«¤ë¤È¡¢Â­²¼¤ò¤¹¤¯¤ï¤ì¤Þ¤¹¡£

º£Ç¯¤Î£µ·î£²£°Æü¤Ë³«ºÅ¤µ¤ì¤¿¡¢¡¡ÆüËÜÌôºÞ±Ö³Ø²ñ¼çºÅ¡¢¡Ö¥¤¥ó¥Õ¥ë¥¨¥ó¥¶Øí´µ¸å¤Î°Û¾ï¹ÔÆ°¤ÈÌôºÞ±Ö³Ø¡×¤È¤¤¤¦ÆÃÊÌ¥·¥ó¥Ý¥¸¥¦¥à¤Î¥ì¥Ý¡¼¥È¤Ç¤¹¡£
http://www.blwisdom.com/blog/shikano/archives/2007/07/post_105.html
¡¡¤Ê¤ó¤Ç¤â¡ÖÌô³²¡×¤Ã¤Æ´ÑÅÀ¤«¤é¤À¤È¡¢¡Ö¡©¡×¤Ë»×¤¦¡£
¤¢¤Î»ö·ï¤Ë¤â¡¦¡¦¡¦¤³¤ó¤Ê¶ñ¹ç¤Ç¡¦¡¦¡¦
¢­
ÊÔ½¸Ä¹¥¤¥ó¥¿¥Ó¥å¡¼¡¡¤è¤ê
ÆàÎɸ©ÂçÍäĮΩɱ¡¡¡ÊìÂλàË´»ö¸Î¤Î¿¿Áê¡¡¡¡¹âºê¿¸Ê夵¤ó¤Ëʹ¤¯
http://www.npojip.org/contents/book/mag028.html
¤È¤«°Î¤¤»ö¸À¤Ã¤È¤¤¤Æ¼«Ê¬¤Î°ìºÐ¤Î¥¬¥­¤ËÉ÷¼Ù¤Ò¤¤¤Æ³±¤­¤Ç¤¿»þ¤Ë²ø¤·¤¤Ìô¤¢¤²¤¿¤³¤È¤¢¤ê¤Þ¤¹¡£Á´Á³¸ú¤­¤Þ¤»¤ó¤ó¤Ç¤·¤¿¡£¤µ¤¹¤¬¤Ë¹³À¸Êª¼Á¤Ï¤ä¤ê¤Þ¤»¤ó¤Ç¤·¤¿¡£ºá°­´¶¤ò´¶¤¸¤¿¤Î¤Ç¥¹¥Ý¥ó¥¸¥Ü¥Ö¥¹¥¯¥¥¥¨¥¢¡¼¥Ñ¥ó¥Ä¤Î²Ã¼¾´ï¤òÇ㤤Ϳ¤¨¤¿¤é¤¹¤°¼£¤ê¤Þ¤·¤¿¡£¤Ç¤­¤ì¤Ð¥À¥Ö¥ë¥Ö¥é¥¤¥ó¥Ç¥Ã¥É¥é¥ó¥À¥Þ¥¤¥º¥É¥×¥í¥¹¥Ú¥¯¥Æ¥£¥ô¥¯¥ê¥Ë¥«¥ë¥È¥é¥¤¥¢¥ë¤ò¤·¤¿¤¤¤â¤Î¤Ç¤¹¡£

ÆÉÇä¤Î¿·Ê¹¤È¤·¤Æ¤Î¼Á¤ò¹Í¤¨¤ì¤Ðð÷¤±¤Þ¤¹¤Í¡£

>>17

¤«¤ï¤¤¤¤¥Ù¡¼¥Ý¥é¥¤¥¶¡¼¤Ç¤¹¤Í¡£
¾øµ¤¤ÎÍͻҤ«¤é¸«¤ë¤È¥¤¥ª¥ó¼°¤Ç¤·¤ç¤¦¤«¤Í¡©
²ÃÇ®¼°¤À¤È¶á¤Å¤¤¤¿¤é´í¤Ê¤¤¤Ç¤¹¤«¤é¤Í¡£

double blinded randomized prospective clinical trial : Æó½ÅÌÕ¼°Ìµºî°Ù¥×¥í¥¹¥Ú¥¯¥Æ¥£¥ÖÎ×¾²»î¸³
°å³ØÍѸìŪ¤Ë¤Ï¡¡Á°¸þ¤­Ìµºî°Ù¡Ê²½¡ËÆó½ÅÌÕ¸¡Î×¾²»î¸³¡¡¤¬¥Ý¥Ô¥å¥é¡¼¤Ç¤¹¤«¤Í¡£
prospective randomized double blinded clinical trial¤¬ÉáÄ̤θÀ¤¤Êý¤Ê¤ó¤Ç¤·¤ç¤¦¤Í¡©
°ìÈÖµ¤¤Ë¤Ê¤Ã¤¿¤Î¤Ï¡¢¡ÖÌÕ¼°¡×¤Ç¤·¤¿¡£½çÈ֤ϡ¢¤Þ¤¡¿§¡¹¸À¤¦¿Í¤Ï¤¤¤Þ¤¹¡£
¤³¤ÎÏÀʸÃø¼Ô¤Ê¤ó¤«¤Ï¥Í¥¤¥Æ¥£¥Ö¤Ã¤Ý¤¤¤Ç¤¹¤¬¡¢"A Prospective, Randomized, Double-Blind Trial" ¤ò»È¤Ã¤Æ¤¤¤Þ¤¹¤Í¡£
¢­
http://www.maruishi-pharm.co.jp/medical/iche/2007/03/03_12.html
¤½¤ì¤È¡¢¤Ì¤Ó¤µ¤ó¤òÁ°¤Ë¡¢¼«¿®¤¬Ìµ¤¤¤Î¤Ç¤¹¤¬¡¢blind¤Ï·ÁÍÆ»ì¤Ê¤Î¤Ë²áµî·Á¤¬¤¢¤ë¤Î¤«¡©¡¡¤È¤¤¤¦µ¿Ìä¤âÌ©¤«¤ËÊú¤¤¤Æ¤¤¤Þ¤¹¡£
¾ư»ì¤Ç¤â¤¢¤ë¤Î¤Ç²áµî·Á¤Ï¤¢¤ë¤Ç¤·¤ç¡£
¤¢¤ê¤¬¤È¤¦¤´¤¶¤¤¤Þ¤·¤¿¡£Â¾Æ°»ì¤â¤¢¤ë¤ó¤Ç¤¹¤Í¡£
¤Ü¤¯¤Î¸«¤¿¼­½ñ¤¬¸Å¤¤¤Î¤«¤È»×¤Ã¤Æ³Îǧ¤·¤¿¤é¡¢¤·¤ç¤¦¤ï£´£´Ç¯¤Î¤â¤Î¤Ç¤¹¤¿¡£orz

¤Ä¤¤¤Ç¤Ë¡¢´Ö°ã¤¨¤¿µ¤¤¬¤·¤Þ¤¹¡£¡¡²áµî·Á¢ª²áµîʬ»ì¡¡m(_ _)m
¤¢¡¢¤½¤¦¤Ç¤¹¤Í¡£
²áµîʬ»ì¡£
»ä¡¢Ê¸Ë¡¤Ë¤Ï¼å¤¤¤Î¤Ç¤¹¡£
´¶³Ð¤À¤±¤Ê¤Î¤Ç¡¢¤¹¤ß¤Þ¤»¤ó¡£
±Ñ¼­Ïº¤Ë¡ÖÆó½ÅÌÕ¼°¡×¤Ã¤Æ½Ð¤Æ¤ë¤ó¤Ç¤¹¤Í¡£Ëͤ¬ÃΤé¤Ê¤¤¤À¤±¤«¤â¤Ê¤¡¡Á¡£
http://eow.alc.co.jp/blinded/UTF-8/

¡Ê¥¤¥á¡¼¥¸Åª¤Ë¤Ïblind¤µ¤ì¤ë¤Î¤ÏÈ︳¼Ô¤Ê¤ó¤À¤±¤É¤Ê¡Á¡Ë
¤¤¤ä¡¢»ä¤ÏÁǿͤDz¿¤Ë¤âÃΤê¤Þ¤»¤ó¤«¤é¡¢¼ÂÃϤǤä¤Ã¤Æ¤é¤Ã¤·¤ã¤ëÀèÀ¸¤Î¤Û¤¦¤¬Àµ¤·¤¤¤È»×¤¤¤Þ¤¹¤è¡£
ÏÀʸ¤ÏºÇ¶á½ñ¤¤¤Æ¤Ê¤¤¤ó¤Ç¤¹¤è¡£¡Ê¾Ð¡Ë
¤¢¤ó¤Þ¤ê¿¿·õ¤Ë¹Í¤¨¤º¤Ë¥Æ¥±¥Æ¥±½ñ¤¤¤Æ¤Þ¤·¤¿¤¬¤Þ¤¢½çÈÖ¤â½ÅÍפ«¤â¤·¤ì¤Þ¤Ø¤ó¤Ê¡£¤¢¤È¥Ö¥é¥¤¥ó¥Ç¥Ã¥É¤Í¡£¤¢¤ì¤Ï¤É¤¦¤Ê¤ó¤Ç¤¹¤«¤Í¡£¤¿¤È¤¨¤Ð"The clinicians were blinded as to which group receive the medication"¤È¤«¤¤¤¤¤Þ¤¹¤«¤é¥Ö¥é¥¤¥ó¥Ç¥Ã¥É¤Ã¤Æ¤¤¤Ã¤¿Ìõ¤Ç¤¹¤è¡£ºÙ¤«¤¤¤Ç¤¹¤Í¡£Å·ÇéºÂ
¤¤¤Á¤ã¤â¤ó¤Ã¤Ý¤¤¤Ç¤¹¤±¤ì¤É¡¢¤³¤¦¤¤¤¦ÅÀ¤ò²ò¾Ã¤¹¤ë¤Î¤¬¹¥¤­¤Ê¤À¤±¤Ç¡¢°­µ¤¤Ï¤Ê¤¤¤Î¤Ç¤¹¡£¤´¤á¤ó¤Ê¤µ¤¤¡£m(_ _)m
¡ä£±£°¡¤£±£±
¸À¤ï¤ì¤Æ¤ß¤ì¤Ð³Î¤«¤Ë¡£
ÂÑÀ­¶Ý¤ÎÌäÂê¤â¤¢¤ê¤Þ¤¹¤â¤ó¤Í
³ØÀ¸»þÂ奢¥á¥ê¥«¤Î¥É¥é¥Ã¥°¥¹¥È¥¢¤Ë
¥Ú¥Ë¥·¥ê¥ó¤Ê¤É¤¬¼ê¤Ë¼è¤ì¤ë½ê¤Ëʤó¤Ç¤¿
¤½¤Î°õ¾Ý¤¬¶¯¤«¤Ã¤¿¤â¤Î¤ÇŽ¥Ž¥Ž¥

¡ä£±£²
¥¹¥¤¥Þ¥»¥ó»ú¤ò´Ö°ã¤¨¤Æ¤Þ¤·¤¿
ÈÖĹ¢ª¡ß
ÈÙĹ¢ª¡û
¤ªÏͤӤ·¤Þ¤¹¡£

¡ä£²£¹
Ëͤâ
double blinded randomized prospective clinical trial
£Ä£Â£Ò£Ã£Ô
¤Ç½¬¤¤¤Þ¤·¤¿¤±¤É¡¢ÏÀʸ¤Ë¤è¤Ã¤Æ
¸ÀÍդϤޤÁ¤Þ¤Á¤À¤Ã¤¿¤ê¤·¤Þ¤¹¤è¡£




¡ä£±£µ¡¤£±£¶
ËͤϼºÝÉÍϻϺ»á¤ÎÏäòľÀÜÄ°¤¤¤¿¤³¤È¤Ï¤Ê¤¤¤Î¤Ç¤¹¤¬¡¦¡¦¡¦
°ìÅÙµ¡²ñ¤¬¤¢¤ì¤ÐÄ°¤¤¤Æ¤ß¤¿¤¤¤Ç¤¹¤Í¡£

¥í¥°¥¤¥ó¤¹¤ë¤È¡¢»Ä¤ê7·ï¤Î¥³¥á¥ó¥È¤¬¸«¤ì¤ë¤è

mixi¥æ¡¼¥¶¡¼
¥í¥°¥¤¥ó¤·¤Æ¥³¥á¥ó¥È¤·¤è¤¦¡ª

mixiÁí¹ç°åÎÅ¥»¥ó¥¿¡¼ ¹¹¿·¾ðÊó

mixiÁí¹ç°åÎÅ¥»¥ó¥¿¡¼¤Î¥á¥ó¥Ð¡¼¤Ï¤³¤ó¤Ê¥³¥ß¥å¥Ë¥Æ¥£¤Ë¤â»²²Ã¤·¤Æ¤¤¤Þ¤¹

À±°õ¤Î¿ô¤Ï¡¢¶¦Ä̤·¤Æ»²²Ã¤·¤Æ¤¤¤ë¥á¥ó¥Ð¡¼¤¬Â¿¤¤¤Û¤ÉÁý¤¨¤Þ¤¹¡£